Boston, MA 08/28/2014 (wallstreetpr) – EBOLA has created a huge buzz around the world in very limited time. Hundreds of people have died due to this deadly virus which has not any cure. Scientists from all around the world have been trying their best to find any vaccine for EBOLA virus for a long time without any success. Although an experimental vaccine developed by GlaxoSmithKline plc (ADR) (NYSE:GSK) has got the attention of everyone. According to GSK, this vaccine can cure EBOLA. Scientists will start the enrollments of patients for clinical trial of this experimental vaccine. The process is expected to start from the next week.
Phase 1 to start soon:
EBOLA has caused a lot of deaths in West Africa as well as other parts of the world. The virus will soon take over the entire world if scientists fail to find any vaccine for it soon. During a telephonic interview, Michael Kurilla, Director of the Office of Bio-defense, Research Resources and Translational Research, said, “Food and Drug Administration gave the approval to National Institutes of Health’s Vaccine Research Center to start the first phase of experimental trial.”
Scientists tested the vaccine in animals and got positive results that prompted them to try it in humans as well. The first phase of this trial will ensure if the vaccine is safe and harmless for the humans. It will also reveal if the vaccine can show similar results in humans as it did in animals. As per the government record, EBOLA outbreak has so far killed 1427 people in four country, but if government doesn’t pay any attention, then it can kill number of people in the near future than the current number of all four countries put together. GlaxoSmithKline plc (ADR) (NYSE:GSK) and NIH are working together to develop the experimental vaccine for EBOLA, which doesn’t contain any harmful ingredient.